Skip to content

Immix Biopharma, Inc. IMMX Operating lease liabilities

Operating lease liabilities at other companies

Allogene Therapeutics logo
Allogene TherapeuticsALLO
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
Immunome logo
ImmunomeIMNM
Precigen logo
PrecigenPGEN
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s operating lease liabilities?
Immix Biopharma, Inc. (IMMX) reported operating lease liabilities of -$35.23K in Q1 2026.
How has Immix Biopharma, Inc.'s operating lease liabilities changed year-over-year?
Immix Biopharma, Inc.'s operating lease liabilities decreased by 122.6% year-over-year, from -$15.83K to -$35.23K.